3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
10
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Neurotoxicity Syndromes
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Hemorrhage
2
Chronic Pain
2
Agnosia
2
Vulvodynia
1
Uterine Cervical Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Radiodermatitis
1
Radiation Injuries
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Interventions
Dacarbazine
4
pembrolizumab
3
binimetinib
3
Nivolumab
3
encorafenib
2
cemiplimab
2
Sirolimus
2
Ipilimumab
2
vitespin
1
trametinib
1
tilsotolimod
1
spartalizumab
1
oblimersen
1
linrodostat
1
lifileucel
1
gp100 Melanoma Antigen
1
dabrafenib
1
bempegaldesleukin
1
aldesleukin
1
Vinblastine
1
Vemurafenib
1
Tretinoin
1
Tacrolimus
1
Standard of Care
1
Sodium Chloride
1
Radiotherapy
1
Radiation
1
Interleukin-2
1
Interferon-alpha
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Skin Neoplasms
×
Sodium Chloride
×
Clear all
NCT00518895
2011-11-07
AGENDA
Genta Incorporated
Phase 3
Completed
300 enrolled